# OnCo record idea-tr1-immunotherapy-stop-trials (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr1-immunotherapy-stop-trials/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr1-immunotherapy-stop-trials" ;
  schema:name "Randomised trials of stopping immunotherapy after one year versus continuing"@en ;
  schema:description "Immunotherapy is often given for two years or until it stops working, but responses can last long after stopping. Trials that randomly assign responders to stop or continue would show whether the extra year is needed."@en ;
  schema:url <https://onco.cc/ideas/idea-tr1-immunotherapy-stop-trials/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1136/bmj.j4530> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-227/>, <https://onco.cc/trials/checkmate-915/>, <https://onco.cc/trials/fianlimab-phase3-melanoma/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/relativity-098/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-davis-bmj/>, <https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/>, <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-keynote-010-lancet-2016/> .